Engineered Nanoparticles Form Nanoplatform to Target Glioblastoma

Glioblastoma (GBM) is the most common and highly malignant cancer in the adult brain, characterized by poor prognosis and aggressive infiltration. A long-standing problem in GBM treatment is the delivery of therapeutics to brain-invading tumor cells that is obstructed by the blood−brain barrier (BBB). Immune checkpoint blocker-based combination therapy stands critical for GBM treatment.